YO40482: A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER
Study of Cobimetinib with Niraparib, With or Without Atezolizumab, in Patients with Advanced Platinum-Sensitive Ovarian Cancer
Sponsor: F. Hoffmann-La Roche Ltd
Enrolling: Female Patients Only
IRB Number: AAAS0353
U.S. Govt. ID: NCT03695380
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out what effects, good or bad, cobimetinib and niraparib, given with or without atezolizumab, have on you and your cancer. In this study, you will receive either cobimetinib plus niraparib or cobimetinib plus niraparib plus atezolizumab. In addition, if you are assigned to receive cobimetinib and niraparib and your cancer progresses, you could receive atezolizumab along with cobimetinib and niraparib if your doctor believes that you may benefit from this treatment.
This study is closed
Investigator
Jason Wright, MD
Do You Qualify?
Have you been diagnosed with endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer? Yes No
Have you received 1-2 prior platinum-containing treatment regimens? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE